These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 21154590)

  • 1. Prognostic impact of MYCN, DDX1, TrkA, and TrkC gene transcripts expression in neuroblastoma.
    de Souza DR; Sanabani SS; de Souza AC; Filho Odone V; Epelman S; Bendit I
    Pediatr Blood Cancer; 2011 May; 56(5):749-56. PubMed ID: 21154590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship of DDX1 and NAG gene amplification/overexpression to the prognosis of patients with MYCN-amplified neuroblastoma.
    Kaneko S; Ohira M; Nakamura Y; Isogai E; Nakagawara A; Kaneko M
    J Cancer Res Clin Oncol; 2007 Mar; 133(3):185-92. PubMed ID: 17028906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coamplification of DDX1 correlates with an improved survival probability in children with MYCN-amplified human neuroblastoma.
    Weber A; Imisch P; Bergmann E; Christiansen H
    J Clin Oncol; 2004 Jul; 22(13):2681-90. PubMed ID: 15226335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance.
    Shimada H; Nakagawa A; Peters J; Wang H; Wakamatsu PK; Lukens JN; Matthay KK; Siegel SE; Seeger RC
    Cancer; 2004 Oct; 101(8):1873-81. PubMed ID: 15386308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concomitant DDX1 and MYCN gain in neuroblastoma.
    Defferrari R; Tonini GP; Conte M; Papio F; Sementa AR; Valent A; Schena F; Perri P; Mazzocco K
    Cancer Lett; 2007 Oct; 256(1):56-63. PubMed ID: 17611020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR.
    Oberthuer A; Kaderali L; Kahlert Y; Hero B; Westermann F; Berthold F; Brors B; Eils R; Fischer M
    Clin Cancer Res; 2008 Oct; 14(20):6590-601. PubMed ID: 18927300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Classification of neuroblastomas based on an analysis of the expression of genes related to prognosis.
    Tajiri T; Higashi M; Souzaki R; Tatsuta K; Kinoshita Y; Taguchi T
    J Pediatr Surg; 2007 Dec; 42(12):2046-9. PubMed ID: 18082705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The MYCN enigma: significance of MYCN expression in neuroblastoma.
    Tang XX; Zhao H; Kung B; Kim DY; Hicks SL; Cohn SL; Cheung NK; Seeger RC; Evans AE; Ikegaki N
    Cancer Res; 2006 Mar; 66(5):2826-33. PubMed ID: 16510605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling.
    Schramm A; Schulte JH; Klein-Hitpass L; Havers W; Sieverts H; Berwanger B; Christiansen H; Warnat P; Brors B; Eils J; Eils R; Eggert A
    Oncogene; 2005 Nov; 24(53):7902-12. PubMed ID: 16103881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The studies on the correlation for gene expression of tyrosine-kinase receptors and vascular endothelial growth factor in human neuroblastomas.
    Zhang J; Zheng Y; Wang Y; Tong H
    J Pediatr Hematol Oncol; 2010 Apr; 32(3):180-4. PubMed ID: 20186105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shc family expression in neuroblastoma: high expression of shcC is associated with a poor prognosis in advanced neuroblastoma.
    Terui E; Matsunaga T; Yoshida H; Kouchi K; Kuroda H; Hishiki T; Saito T; Yamada S; Shirasawa H; Ohnuma N
    Clin Cancer Res; 2005 May; 11(9):3280-7. PubMed ID: 15867224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A MYCN-amplified cell line derived from a long-term event-free survivor among our sixteen established neuroblastoma cell lines.
    Sugimoto T; Gotoh T; Yagyu S; Kuroda H; Iehara T; Hosoi H; Ohta S; Ohira M; Nakagawara A
    Cancer Lett; 2013 Apr; 331(1):115-21. PubMed ID: 23268333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of biologic factors on the surgical decision in advanced neuroblastoma.
    Hsu WM; Jen YM; Lee H; Kuo ML; Tsao PN; Chen CN; Lai DM; Lin MT; Lai HS; Chen WJ; Hsieh FJ
    Ann Surg Oncol; 2006 Feb; 13(2):238-44. PubMed ID: 16418884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroblastomas with discordant genotype-phenotype relationships: report of four cases with MYCN amplification and favorable histology.
    Nakagawa A; Matsuoka K; Okita H; Iwafuchi H; Hori H; Kumagai M
    Pediatr Dev Pathol; 2011; 14(2):87-92. PubMed ID: 21288077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression of TRK neurotrophin receptors in advanced neuroblastomas in Singapore--a pilot study.
    Fung W; Hasan MY; Loh AH; Chua JH; Yong MH; Knight L; Hwang WS; Chan MY; Seow WT; Jacobsen AS; Chui CH
    Pediatr Hematol Oncol; 2011 Oct; 28(7):571-8. PubMed ID: 21728718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroblastoma messenger RNA is frequently detected in bone marrow at diagnosis of localised neuroblastoma patients.
    van Wezel EM; Decarolis B; Stutterheim J; Zappeij-Kannegieter L; Berthold F; Schumacher-Kuckelkorn R; Simon T; Fiocco M; van Noesel MM; Caron HN; van der Schoot CE; Hero B; Tytgat GAM
    Eur J Cancer; 2016 Feb; 54():149-158. PubMed ID: 26796600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Study on MYCN gene amplification and CD44 expression in neuroblastoma].
    Hu HL; He LJ
    Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Full-length telomerase reverse transcriptase messenger RNA is an independent prognostic factor in neuroblastoma.
    Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P
    Am J Pathol; 2003 Mar; 162(3):1019-26. PubMed ID: 12598334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of NTRK family gene expression in neuroblastomas.
    Light JE; Koyama H; Minturn JE; Ho R; Simpson AM; Iyer R; Mangino JL; Kolla V; London WB; Brodeur GM
    Pediatr Blood Cancer; 2012 Aug; 59(2):226-32. PubMed ID: 21990266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index.
    Kobayashi C; Monforte-Munoz HL; Gerbing RB; Stram DO; Matthay KK; Lukens JN; Seeger RC; Shimada H
    Cancer; 2005 Jan; 103(1):174-80. PubMed ID: 15549714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.